AMI Asset Management Corp raised its position in Colgate-Palmolive Company (NYSE:CL - Free Report) by 39.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 537,438 shares of the company's stock after buying an additional 153,254 shares during the period. Colgate-Palmolive comprises about 2.8% of AMI Asset Management Corp's portfolio, making the stock its 16th largest holding. AMI Asset Management Corp owned approximately 0.07% of Colgate-Palmolive worth $48,853,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Colgate-Palmolive by 18.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,009,078 shares of the company's stock worth $3,186,651,000 after purchasing an additional 5,269,140 shares during the last quarter. Nuveen LLC acquired a new position in shares of Colgate-Palmolive during the 1st quarter worth approximately $217,593,000. Goldman Sachs Group Inc. boosted its holdings in shares of Colgate-Palmolive by 34.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 7,980,387 shares of the company's stock worth $747,762,000 after purchasing an additional 2,045,191 shares during the last quarter. Diamond Hill Capital Management Inc. boosted its holdings in shares of Colgate-Palmolive by 45.0% during the 1st quarter. Diamond Hill Capital Management Inc. now owns 5,562,968 shares of the company's stock worth $521,250,000 after purchasing an additional 1,727,105 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of Colgate-Palmolive by 60.5% during the 1st quarter. Alliancebernstein L.P. now owns 2,336,783 shares of the company's stock worth $218,957,000 after purchasing an additional 880,527 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors and hedge funds.
Colgate-Palmolive Stock Performance
NYSE:CL opened at $78.95 on Thursday. The company has a fifty day simple moving average of $83.69 and a two-hundred day simple moving average of $88.50. The company has a market cap of $63.81 billion, a price-to-earnings ratio of 22.18, a price-to-earnings-growth ratio of 4.16 and a beta of 0.34. The company has a quick ratio of 0.57, a current ratio of 0.89 and a debt-to-equity ratio of 6.79. Colgate-Palmolive Company has a 52 week low of $78.76 and a 52 week high of $102.61.
Colgate-Palmolive (NYSE:CL - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.89 by $0.03. The business had revenue of $5.11 billion during the quarter, compared to the consensus estimate of $5.03 billion. Colgate-Palmolive had a net margin of 14.55% and a return on equity of 377.63%. The company's quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.91 earnings per share. As a group, equities analysts anticipate that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.
Colgate-Palmolive Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Friday, October 17th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, October 17th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.6%. Colgate-Palmolive's payout ratio is presently 58.43%.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on CL. Wells Fargo & Company reduced their price target on shares of Colgate-Palmolive from $83.00 to $80.00 and set an "underweight" rating on the stock in a research report on Thursday, September 25th. Citigroup reduced their price target on shares of Colgate-Palmolive from $108.00 to $105.00 and set a "buy" rating on the stock in a research report on Monday, August 4th. Morgan Stanley reduced their price target on shares of Colgate-Palmolive from $104.00 to $96.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. JPMorgan Chase & Co. reduced their price target on shares of Colgate-Palmolive from $99.00 to $95.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. Finally, UBS Group reduced their price target on shares of Colgate-Palmolive from $109.00 to $106.00 and set a "buy" rating on the stock in a research report on Thursday, July 17th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $97.27.
Check Out Our Latest Stock Report on CL
Colgate-Palmolive Profile
(
Free Report)
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
Further Reading
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Colgate-Palmolive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.
While Colgate-Palmolive currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.